[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Serina Therapeutics Inc (SER)

Serina Therapeutics Inc (SER)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,116
  • Shares Outstanding, K 14,899
  • Annual Sales, $ 130 K
  • Annual Income, $ -19,180 K
  • EBIT $ -23 M
  • EBITDA $ -23 M
  • 60-Month Beta 1.21
  • Price/Sales 209.73
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.27
  • Growth Rate Est. (year over year) +370,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7406 +3.41%
on 04/30/26
2.3000 -21.74%
on 04/13/26
-0.3200 (-15.09%)
since 04/01/26
3-Month
1.2200 +47.54%
on 03/18/26
3.2900 -45.29%
on 03/23/26
-1.4500 (-44.62%)
since 01/30/26
52-Week
1.2200 +47.54%
on 03/18/26
7.9200 -77.27%
on 08/26/25
-3.5100 (-66.10%)
since 05/01/25

Most Recent Stories

More News
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

– Novel lipid nanoparticles entirely built on the POZ Platform that overcome the PEG immunogenicity dilemma – Design & synthesis of novel ionizable POZ lipids to replace current ionizable lipids...

SER : 1.8000 (-1.10%)
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

HUNTSVILLE, April 02, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform...

SER : 1.8000 (-1.10%)
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

- FDA Grants IND Clearance for SER-252 - SER-252 Phase 1b Trial Initiated - Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE)...

SER : 1.8000 (-1.10%)
Serina Therapeutics to Present at the 38th Annual Roth Conference

HUNTSVILLE, AL, March 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™  drug...

SER : 1.8000 (-1.10%)
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease

- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded warrants...

SER : 1.8000 (-1.10%)
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease

- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 – - Advancement reflects continued execution...

SER : 1.8000 (-1.10%)
Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

- First patient successfully enrolled in global registrational study in Australia  - Operational presence in Australia positions Serina to advance enrollment in Cohort 1 - Company remains on track...

SER : 1.8000 (-1.10%)
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event

“Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences"  Featuring Serina Therapeutics’ CEO - Wednesday, February 4, 2026 Hear how FDA initiatives in 2026...

SER : 1.8000 (-1.10%)
Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity

HUNTSVILLE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc.  (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational...

SER : 1.8000 (-1.10%)
Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

HUNTSVILLE, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc.  (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational...

SER : 1.8000 (-1.10%)

Business Summary

Serina Therapeutics Inc. is a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson's Disease and other neurological diseases. Serina Therapeutics Inc., formerly known as AgeX Therapeutics Inc., is based in HUNTSVILLE, Ala.

See More

Key Turning Points

3rd Resistance Point 1.9759
2nd Resistance Point 1.9129
1st Resistance Point 1.8665
Last Price 1.8000
1st Support Level 1.7571
2nd Support Level 1.6941
3rd Support Level 1.6477

See More

52-Week High 7.9200
Fibonacci 61.8% 5.3606
Fibonacci 50% 4.5700
Fibonacci 38.2% 3.7794
Last Price 1.8000
52-Week Low 1.2200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.